From Wikipedia, the free encyclopedia
Recombinant human tissue kallikrein-1 , also known as DM199, is an experimental drug that acts on the
kallikrein-kinin system and is developed for diabetes.
[1]
[2]
[3]
[4]
^ Maneva-Radicheva, Lilia; Amatya, Christina; Parker, Camille; Ellefson, Jacob; Radichev, Ilian; Raghavan, Arvind; Charles, Matthew L.; Williams, Mark S.; Robbins, Mark S.; Savinov, Alexei Y. (26 September 2014).
"Autoimmune Diabetes Is Suppressed by Treatment with Recombinant Human Tissue Kallikrein-1" . PLOS ONE . 9 (9): e107213.
Bibcode :
2014PLoSO...9j7213M .
doi :
10.1371/journal.pone.0107213 .
PMC
4178025 .
PMID
25259810 .
^ Charest-Morin, Xavier; Raghavan, Arvind; Charles, Matthew L.; Kolodka, Tadeusz; Bouthillier, Johanne; Jean, Mélissa; Robbins, Mark S.; Marceau, François (March 2015).
"Pharmacological effects of recombinant human tissue kallikrein on bradykinin B 2 receptors" . Pharmacology Research & Perspectives . 3 (2): e00119.
doi :
10.1002/prp2.119 .
PMC
4448978 .
PMID
26038695 .
^ Kolodka, Tadeusz; Charles, Matthew L.; Raghavan, Arvind; Radichev, Ilian A.; Amatya, Christina; Ellefson, Jacob; Savinov, Alexei Y.; Nag, Abhijeet; Williams, Mark S.; Robbins, Mark S. (6 August 2014).
"Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus" . PLOS ONE . 9 (8): e103981.
Bibcode :
2014PLoSO...9j3981K .
doi :
10.1371/journal.pone.0103981 .
PMC
4123992 .
PMID
25100328 .
^ Alexander-Curtis, Michelle; Pauls, Rick; Chao, Julie; Volpi, John J; Bath, Philip M; Verdoorn, Todd A. (January 2019).
"Human tissue kallikrein in the treatment of acute ischemic stroke" . Therapeutic Advances in Neurological Disorders . 12 : 175628641882191.
doi :
10.1177/1756286418821918 .
PMC
6348491 .
PMID
30719079 .